相似文献
1
Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.
Oncologist. 2014 Sep;19(9):1006-7. doi: 10.1634/theoncologist.2014-0054. Epub 2014 Aug 1.
2
Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.
Oncogene. 2020 Sep;39(36):5867-5875. doi: 10.1038/s41388-020-01404-x. Epub 2020 Jul 28.
3
Clinical significance of ERBB2 S310F mutation in extramammary Paget's disease.
J Dermatol. 2022 Sep;49(9):e305-e306. doi: 10.1111/1346-8138.16439. Epub 2022 May 17.
4
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
Oncotarget. 2019 Nov 19;10(62):6647-6650. doi: 10.18632/oncotarget.27272.
5
Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget's disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget's disease patients.
Cancer Immunol Immunother. 2024 Oct 3;73(12):252. doi: 10.1007/s00262-024-03846-8.
6
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Invest New Drugs. 2016 Jun;34(3):394-6. doi: 10.1007/s10637-016-0329-8. Epub 2016 Feb 9.
7
Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget's disease: Four cases and a review.
J Dermatol. 2020 Nov;47(11):1276-1279. doi: 10.1111/1346-8138.15515. Epub 2020 Jul 24.
8
Whole genome sequencing of HER2-positive metastatic extramammary Paget's disease: a case report.
Orphanet J Rare Dis. 2024 Jun 3;19(1):223. doi: 10.1186/s13023-024-03169-y.
9
Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.
Clin Exp Metastasis. 2016 Oct;33(7):687-97. doi: 10.1007/s10585-016-9804-z. Epub 2016 Jun 11.
10
p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease.
Mod Pathol. 2005 Mar;18(3):354-7. doi: 10.1038/modpathol.3800243.
引用本文的文献
1
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
Discov Oncol. 2024 Jul 16;15(1):285. doi: 10.1007/s12672-024-01154-2.
2
Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism.
Br J Cancer. 2024 Sep;131(5):944-953. doi: 10.1038/s41416-024-02788-3. Epub 2024 Jul 10.
3
Identification of Predictive Factors for Post-operative Recurrence and Clinical Outcomes of Primary Vulvar Extramammary Paget Disease.
In Vivo. 2023 Nov-Dec;37(6):2618-2627. doi: 10.21873/invivo.13369.
4
HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses.
Cancers (Basel). 2022 Jul 20;14(14):3519. doi: 10.3390/cancers14143519.
5
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Oncologist. 2021 Mar;26(3):e394-e402. doi: 10.1002/onco.13597. Epub 2020 Dec 14.
6
An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers.
Gynecol Oncol Rep. 2020 May 1;32:100577. doi: 10.1016/j.gore.2020.100577. eCollection 2020 May.
7
Somatic Mutations in and Implications for Current Treatment Paradigms in -Positive Breast Cancer.
J Oncol. 2020 Mar 7;2020:6375956. doi: 10.1155/2020/6375956. eCollection 2020.
8
Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
Cancer Med. 2020 Feb;9(4):1441-1450. doi: 10.1002/cam4.2820. Epub 2020 Jan 3.
9
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
Oncotarget. 2019 Nov 19;10(62):6647-6650. doi: 10.18632/oncotarget.27272.
10
Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.
Oncotarget. 2019 Oct 22;10(58):6152-6167. doi: 10.18632/oncotarget.27247.
本文引用的文献
1
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7.
2
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. doi: 10.1073/pnas.1203201109. Epub 2012 Aug 20.
3
A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy.
Case Rep Dermatol. 2011 Sep;3(3):223-7. doi: 10.1159/000333002. Epub 2011 Oct 11.
4
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50. doi: 10.1093/nar/gkq929. Epub 2010 Oct 15.
5
Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy.
J Dermatol. 2009 Aug;36(8):457-61. doi: 10.1111/j.1346-8138.2009.00676.x.
6
Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.
Hum Pathol. 2005 Dec;36(12):1273-80. doi: 10.1016/j.humpath.2005.09.009. Epub 2005 Oct 28.
7
erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease.
J Invest Dermatol. 1999 Aug;113(2):258-62. doi: 10.1046/j.1523-1747.1999.00634.x.
8
Metastatic extramammary Paget's disease: dramatic response to combined modality treatment.
J Surg Oncol. 1988 May;38(1):38-44. doi: 10.1002/jso.2930380111.
9
Cytoreductive combination chemotherapy for regionally advanced unresectable extramammary Paget carcinoma.
Cancer. 1992 Aug 1;70(3):704-8. doi: 10.1002/1097-0142(19920801)70:3<704::aid-cncr2820700327>3.0.co;2-5.
Zotero 插件